Ara-C and TBI followed by allogeneic bone marrow transplantation is effective therapy for children in second complete remission of their acute leukemia. High-dose therapy and allogeneic matched sibling bone marrow transplantation (BMT) is considered to be the However, significant late toxicities occur, and it is clear that more effective, less toxic therapies are necessary treatment of choice for children with relapsed acute lymphoblastic leukemia (ALL), or for children with for these patients. Keywords: acute lymphocytic leukemia; acute nonacute myeloid leukemia (AML) in first remission. However, the rate of bone marrow relapse after transplant lymphocytic leukemia; cytosine arabinoside for either of these diseases remains high. In this study, we assessed the efficacy and toxicity of high-dose cytosine arabinoside and total body irradiation (TBI) folHigh-dose therapy and allogeneic matched sibling bone lowed by allogeneic BMT, for children with acute leukemarrow transplantation (BMT) is considered by many pedimia or myelodysplastic syndrome (MDS). Sixty-five atric oncologists to be the treatment of choice for children pediatric patients underwent allogeneic related (n = 57) with acute lymphoblastic leukemia who suffer a bone maror unrelated (n = 8) BMT. Twenty-seven were transrow relapse, 1-5 or for children with acute nonlymphoblastic planted for ALL in second remission (CR2), and 16 for leukemia in first complete remission.
(MDS) who underwent allogeneic BMT after high-dose (eight with ALL and one with AML) were transplanted in second or greater relapse, and four of the nine were resistcytosine arabinoside and TBI, over a 13-year period. Included in this group are the 20 patients originally ant to conventional therapy. The remaining three children were transplanted after relapsing after a prior BMT utilizing reported, now with an additional 87 months of follow-up.
a non-TBI-containing regimen (busulfan, cyclophosphamide and VP-16, as previously described 23 ). These patients relapsed 1, 6 and 10 months after their first BMT, and all Methods were in bone marrow relapse at the time of their second transplant. Between 1981 and 1994, 65 pediatric patients (range 1 to 19 years, median 8 years) underwent allogeneic hematoFor the entire group of 22 high-risk patients, 13 children received marrow from HLA-identical sibling donors, two poietic stem cell transplantation at Rainbow Babies and Children's Hospital in Cleveland (1981 Cleveland ( -1986 ), or at the from a one HLA-antigen mismatched sibling or parental donor, and seven from an HLA-phenotypically identical University of Nebraska Medical Center in Omaha (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) . All patients have been followed for a minimum of unrelated donor. 21 months since transplantation.
Therapy Good-risk patients (ALL in CR2, AML in CR1)
All patients were prepared for BMT with cytosine arabinoside 3000 mg/m 2 per dose i.v. (over 2 to 3 hours) twice Twenty-seven patients (median age 7 years, range 1 to 19 years) underwent high-dose therapy and stem cell transdaily for 6 days followed by 1200 cGy TBI as 200 cGy fractions twice daily for 3 days. Marrow was infused on plantation for ALL in second complete remission. All patients were initially treated on Children's Cancer Study the day following completion of TBI. No T lymphocyte depletion was performed in any patient. Four patients (one Group, Pediatric Oncology Group or local institutional protocols. Prior therapy included conventional-dose cytosine with ALL in third remission and three with ALL in relapse) received 600 to 1200 cGy prophylactic testicular arabinoside in 18 cases. All patients achieved remission, but had suffered subsequent relapse a median of 24 months irradiation. One patient with ALL in relapse and a history of CNS leukemia received an additional 600 cGy cranial later (range 3 to 49 months). First relapse occurred in the bone marrow Ϯ extramedullary sites (23 patients), extraradiation immediately prior to TBI. As described above, 51 patients received marrow from HLA-identical sibling medullary site followed by bone marrow (one testicular, one CNS) or extramedullary site alone (one testicular, one donors (including one identical twin), six patients from one HLA-antigen mismatched sibling or parental donors, and testicular and CNS). All of these 27 patients would have been considered at high risk for subsequent relapse.
eight patients from HLA-phenotypically identical unrelated donors. Eighteen patients (67%) had their relapse while on therapy and another six patients (22%) within 6 months of complet-HLA typing for all patients, including those undergoing unrelated donor transplant, was performed by serologic ing therapy. The remaining three patients either had suffered a combined BM and extramedullary relapse or had a methods prior to 1994. High resolution molecular phenotyping of the HLA-DR locus was also performed on all high white blood cell count at diagnosis.
Of the 27 patients transplanted for ALL in second CR, 23 patients undergoing unrelated donor transplant after 1994. All eight patients undergoing unrelated donor transplant received bone marrow from HLA-identical sibling donors (including one identical twin), two from a one class I HLAafter 1994 were identical to their donors at the HLA-DR locus by high resolution molecular phenotyping. antigen mismatched sibling or parental donor, and one from an HLA-phenotypically identical unrelated donor. One Toxicity of the preparative regimen and CNS toxicity were evaluated as previously described. After the first six patient received peripheral blood stem cells collected from his HLA-identical brother, as previously reported. 22 patients were treated, all subsequent patients received glucocorticoid eye drops every 6 to 8 hours during cytosine Sixteen patients (median age 11.5 years, range 5 to 18 years) underwent BMT for AML in first remission. All arabinoside administration. Engraftment was documented by evaluation of peripheral blood counts and examination patients with AML had received prior chemotherapy, including cytosine arabinoside, and all had achieved of the bone marrow in all cases, and by bone marrow or peripheral blood chromosomes in cases where there was remission. Fourteen children received marrow from HLAidentical sibling donors, and two from a one class I HLAa sex difference, or chromosome heteromorphism between donor and patient. antigen mismatched sibling or parental donor.
Prophylaxis against graft-versus-host disease (GVHD) varied considerably over the 13 years of the study. Earlier,
High-risk patients (ALL in CR3, AML in CR2, MDS,
23 patients received no prophylaxis or prednisone alone (2 acute leukemia in relapse) mg/kg/day for 14 days after transplant) as part of a study of the efficacy of GVHD prophylaxis. 24 More recently, 26 Six patients underwent BMT for ALL in third CR, two patients for AML in second CR, and two patients for myepatients received methotrexate (10 mg/m 2 on days 1, 3, 6, 11, 18 and 25 after transplant) with or without prednisone, lodysplastic syndrome. An additional 12 patients were transplanted in relapse of their acute leukemia (ALL eight and eight patients received cyclosporine (3 mg/kg/day from day −1 to day 100 after transplant) with or without methopatients, AML four patients).
Of the 12 children transplanted in relapse, nine children trexate ('short course methotrexate', 15 mg/m 2 on day 1, and 10 mg/m 2 on days 3, 6, and 11 post-transplant). The eight children who received unrelated donor grafts received prophylaxis with antithymocyte globulin (30 mg/kg/dose on days −3, −1, 1, 3, 5, 7, and 9 after transplant), cyclosporine and short course methotrexate with or without prednisone.
Diagnosis and grading of acute and chronic GVHD were by previously established criteria. 25 Treatment of acute GVHD varied somewhat over the course of the study, but generally consisted of systemic corticosteroids with or without ATG. Chronic GVHD treatment also varied, and included various combinations of corticosteroids, cyclosporine, antithymocyte globulin and azathioprine.
Information on delayed effects was obtained by direct phone contact with the patient or his/her parents or guardians, or from the patient's primary physician. Subjects were asked standard questions regarding school and job performance, growth problems, cataracts, pulmonary disease, joint problems and fertility.
All results are analyzed to January 1995. Event-free survival (EFS) is defined as the time from BMT to relapse, second malignancy or death. The EFS was estimated using the product-limit method of Kaplan and Meier.
26 Transplant of Nebraska Medical Center (UNMC). The benefits and the risks of the therapies used were explained in detail to parents and older children and written consent was obtained.
Results

Good-risk patients
Twenty-seven children with ALL were transplanted in second remission. Fifteen are alive without leukemia from 21 to 160 months after BMT (median 98 months) for eventfree survival of 59% (Ϯ9% standard error) at 2 and 5 years after transplant (Figure 1) , and 51% (Ϯ11%) at 10 years after transplant. Two patients have had a bone marrow relapse (13 and 17 months after BMT) for an actuarial relapse rate of 14%.
Sixteen patients with AML were transplanted in first remission. Six are alive without disease from 23 to 142 months after BMT (median 95 months) for EFS of 38% (Ϯ 12%) (Figure 2 ). Only one patient has relapsed (20 months after BMT) for an actuarial relapse rate of 14%. are free of leukemia at 162 and 24 months after transplant, and only one has relapsed (at 29 months after BMT). Two patients underwent BMT for AML in second CR. One is two (both ALL) had isolated testicular relapses 5 and 8 months after BMT, but both patients remain in marrow alive without disease at 50 months and one relapsed at 27 months after BMT. Two patients underwent BMT for remission 38+ and 42+ months after transplant (both 22 months after relapse). Neither patient had received prophy-MDS. One is alive without disease at 31 months after BMT.
Nine patients (eight with ALL and one with AML) were lactic testicular radiation. An additional three patients with AML were transplanted in relapse after a previous nontransplanted in relapse. All nine have had adverse events, including five relapses. Three patients (two ALL, one TBI-containing BMT regimen. All three have had adverse events, including two relapses at 17 and 29 months after AML) relapsed in bone marrow at 1, 3 and 4 months after BMT, and all have died of recurrent leukemia. The other second BMT. One of these patients was subsequently rein-duced and remains in marrow remission 55 months after Oropharyngeal mucositis was seen in all patients and was graded as severe in 40%. One patient with Down's synconventional-dose chemotherapy.
Of the 22 high-risk patients, seven are alive without drome required elective intubation for airway control due to severe mucositis. Conjunctivitis occurred in 66% of leukemia (two in remission after testicular relapses and one in remission after bone marrow relapse), for a EFS of 16% patients, though it appeared to be most severe in early patients who did not receive prophylactic glucocorticoid (Ϯ10%) and an overall survival of 30%. Nine have had bone marrow relapses for an actuarial marrow relapse rate eye drops. One patient developed mild, self-limited, cerebellar dysfunction. That patient had also previously sufof 50%.
fered a CNS relapse of his ALL, and had received 3600 cGy cranial irradiation in addition to aggressive multiagent Engraftment intrathecal chemotherapy. Of the 28 patients alive (including two in remission after Of the 65 patients, 64 showed evidence of hematopoietic engraftment. The one remaining patient died of pulmonary testicular relapse and one in remission after bone marrow relapse), 26 are more than 24 months after BMT. Clinical failure secondary to pulmonary hemorrhage prior to clinical evidence of engraftment, and no post-mortem examination information regarding long-term toxicities was available on 24 of those patients. All patients have Karnofsky scores was obtained. Time to engraftment varied significantly over the course of the study, as some later patients were treated of 90 to 100%. Fourteen patients have had problems with decreased linear growth or short stature, treated with with cytokine (granulocyte-macrophage colony-stimulating factor) after transplantation. Except in children suffering growth hormone in eight cases. Cataracts developed in 10 patients. Poor school performance or learning disabilities bone marrow relapse after transplantation, no patient demonstrated evidence of graft failure. All surviving patients were reported in 10 patients. Seven of these 10 had received 1800 to 2400 cGy cranial irradiation prior to TBI, and two have full trilineage engraftment without transfusion requirements.
patients had CNS leukemia at the time of initial relapse. Avascular necrosis of femoral head or other bone occurred in four patients who all had received prolonged courses of Non-relapse failures and toxicity prednisone as treatment for graft-versus-host disease. Of all 65 patients, 28 have died of causes other than relapse, as detailed in Table 1 . Acute GVHD with or without infection was the cause of death in 11 patients. Ten of the 11 Discussion patients who died of acute GVHD were considered at 'high risk' for GVHD: eight of these 11 patients received inadRelapse after high-dose chemoradiotherapy and bone marrow transplantation remains a major cause of failure in equate GVHD prophylaxis (that is, no methotrexate or cyclosporine) and four of the 11 received marrow from a patients transplanted for ALL or AML. In our hands, highdose cytosine arabinoside and fractionated TBI has been an mismatched family donor or a matched unrelated donor. Patients at 'high risk' were much more likely to die of acute effective and tolerable preparative regimen for children with acute leukemia. We have previously reported a series GVHD than those without these risk factors (P = 0.02 by 2 ). An additional four patients died of chronic GVHD with of 20 patients with ALL in second or third complete remission. In those patients, therapy produced a 2-year EFS or without infection.
One patient developed a glioblastoma multiforme 108 of 58%, and most importantly, a very low marrow relapse rate of 17%. In this current series including 27 children months after BMT, and died 2 months later, in continuous complete remission of his leukemia. He had received extenwith ALL in second remission, event-free survival is 59% at 2 and 5 years after transplant (Figure 1) , and 51% at 10 sive radiation therapy to the brain prior to transplantation: 1800 cGy cranial prophylaxis during primary therapy for years after transplant, and the actuarial relapse rate is 14%. The median follow-up is 98 months. this leukemia, then an additional 1500 cGy to the brain following a CNS relapse.
In addition, we have transplanted 16 children in first remission of AML. The outcome in these patients was less Other toxicities of the preparative regimen included diarrhea (in 50% of patients) and rash (in 47% of patients).
satisfying, with an event-free survival of 38% at a median of 83 months. The actuarial relapse rate for these patients was low at 14%. Finally, treatment of high-risk patients enty percent of the patients in Weyman's report were 16 GVHD = graft-versus-host disease; IP = interstitial pneumonitis.
years of age or younger, and 50% were 11 years of age or younger. The overall 3-year EFS was only 38%, but for toxicity and improve survival of patients with acute leukemia. children less than 11 years of age, the 3 years EFS was 52%, with a relapse rate of about 30%. Toxicity was a problem particularly in older patients. The authors note that References the trend to both low relapse rates and less toxicity in children under 11 years of age suggests that Ara-C and TBI
